1. Fulton RB, Varga SM (2009): Effects of aging on the adaptive immune response to respiratory virus infections. Aging Health 5: 775.
2.
Klein SL (2012): Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases. Bioessays 34: 1050-1059.
3.
Hirzel C, Ferreira VH, L’Huillier AG, et al. (2019): Humoral response to natural influenza infection in solid organ transplant recipients. Am J Transplant 19: 2318-2328.
4.
Silva MJA, Ribeiro LR, Lima KVB, Lima LNGC (2022): Adaptive immunity to SARS-CoV-2 infection: A systematic review. Front Immunol 13: 1001198.
5.
Puro V, Castilletti C, Agrati C, et al. (2021): Impact of prior influenza and pneumoccocal vaccines on humoral and cellular response to SARS-CoV-2 BNT162b2 vaccination. Vaccines (Basel) 9: 615.
6.
Greco M, Cucci F, Portulano P, et al. (2021): Effects of influenza vaccination on the response to BNT162b2 messenger RNA COVID-19 vaccine in healthcare workers. J Clin Med Res 13: 549-555.
7.
Poniedziałek B, Hallmann E, Sikora D, et al. (2022): Relationship between humoral response in COVID-19 and seasonal influenza vaccination. Vaccines (Basel) 10: 1621.
8.
Janeway CA Jr, Travers P, Walport M, Shlomchik MJ (2001): B-cell activation by armed helper T cells. Garland Science, London, England 2001.
9.
Debisarun PA, Gössling KL, Bulut O, et al. (2021): Induction of trained immunity by influenza vaccination - impact on COVID-19. PLoS Pathog 17: e1009928.
10.
Wagstaffe HR, Pickering H, Houghton J, et al. (2019): Influenza vaccination primes human myeloid cell cytokine secretion and NK cell function. J Immunol 203: 1609-1618.
11.
Geckin B, Konstantin Föhse F, Domínguez-Andrés J, Ne- tea MG (2022): Trained immunity: implications for vaccination. Curr Opin Immunol 77: 102190.
12.
Conlon A, Ashur C, Washer L, et al. (2021): Impact of the influenza vaccine on COVID-19 infection rates and severity. Am J Infect Control 49: 694-700.
13.
Wilcox CR, Islam N, Dambha-Miller H (2021): Association between influenza vaccination and hospitalisation or all-cause mortality in people with COVID-19: a retrospective cohort study. BMJ Open Respir Res 8: e000857.
14.
Su W, Wang H, Sun C, et al. (2022): The association between previous influenza vaccination and COVID-19 infection risk and severity: A systematic review and meta-analysis. Am J Prev Med 63: 121-130.
15.
Brydak L, Sikora D, Poniedziałek B, et al. (2023): Association between the seroprevalence of antibodies against seasonal alphacoronaviruses and SARS-CoV-2 humoral immune response, COVID-19 severity, and influenza vaccination. J Clin Med 12: 1733.
16.
Sterlin D, Mathian A, Miyara M, et al. (2021): IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med 13: eabd2223.
17.
Takamatsu Y, Omata K, Shimizu Y, et al. (2022): SARS- CoV-2-neutralizing humoral IgA response occurs earlier but is modest and diminishes faster than IgG response. Microbiol Spectr 10: e0271622.
18.
Genomic epidemiology of SARS-CoV-2 with subsampling focused globally since pandemic start [Internet]. Available from: https://nextstrain.org/ncov/gisaid/global/ (cited 2022 Oct 3).
19.
Flisiak R, Rzymski P, Zarębska-Michaluk D, et al. (2021): Demographic and clinical overview of hospitalized COVID-19 patients during the first 17 months of the pandemic in Poland. J Clin Med 11: 117.
20.
Hoang VT, Colson P, Levasseur A, et al. (2021): Clinical outcomes in patients infected with different SARS-CoV-2 variants at one hospital during three phases of the COVID-19 epidemic in Marseille, France. Infect Genet Evol 95: 105092.
21.
Mathieu E, Ritchie H, Rodés-Guirao L, et al. (2020): Coronavirus pandemic (COVID-19). Our World in Data [Internet]. Available from: https://ourworldindata.org/covid-hospitalizations (cited 2022 Dec 14).
22.
Medić S, Anastassopoulou C, Lozanov-Crvenković Z, et al. (2022): Risk and severity of SARS-CoV-2 reinfections during 2020-2022 in Vojvodina, Serbia: A population-level observational study. Lancet Reg Health Eur 20: 100453.
23.
WHO. Recommendations on influenza vaccination during the 2019-2020 winter season [Internet] (2019). Available from: https://www.euro.who.int/__data/assets/pdf_file/0017/413270/Influenza-vaccine-recommendations-2019-2020_en.pdf (cited 2023 Feb 11).
24.
Montesinos I, Dahma H, Wolff F, et al. (2021): Neutralizing antibody responses following natural SARS-CoV-2 infection: Dynamics and correlation with commercial serologic tests. J Clin Virol 144: 104988.
25.
Kovačić D, Gajić AA, Latinović D, Softić A (2021): Hypothetical immunological and immunogenetic model of heterogenous effects of BCG vaccination in SARS-CoV-2 infections: BCG-induced trained and heterologous immunity. J Med Sci 90: e551.
26.
Kleinnijenhuis J, Quintin J, Preijers F, et al. (2012): Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A 109: 17537-17542.
27.
Higgins JPT, Soares-Weiser K, López-López JA, et al. (2017): Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ 356: j1241.
28.
Tayar E, Abdeen S, Abed Alah M, et al. (2023): Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar. J Infect Public Health 16: 250-256.
29.
Kumar D, Ferreira VH, Campbell P, et al. (2017): Heterologous immune responses to influenza vaccine in kidney transplant recipients. Am J Transplant 17: 281-286.
30.
Netea MG, Domínguez-Andrés J, Barreiro LB, et al. (2020): Defining trained immunity and its role in health and disease. Nat Rev Immunol 20: 375-388.
31.
Smyth P, Sasiwachirangkul J, Williams R, Scott CJ (2022): Cathepsin S (CTSS) activity in health and disease – A treasure trove of untapped clinical potential. Mol Aspects Med 88: 101106.
32.
Ou X, Liu Y, Lei X, et al. (2020): Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 11: 1620.
33.
Bollavaram K, Leeman TH, Lee MW, et al. (2021): Multiple sites on SARS-CoV-2 spike protein are susceptible to proteolysis by cathepsins B, K, L, S, and V. Protein Sci 30: 1131-1143.
34.
Sheikh-Mohamed S, Isho B, Chao GYC, et al. (2022): Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection. Mucosal Immunol 15: 799-808.
35.
Davis SK, Selva KJ, Lopez E, et al. (2022): HeterologousSARS-CoV-2IgAneutralising antibody responses in convalescent plasma. Clin Transl Immunology 11: e1424.
36.
Hennings V, Thörn K, Albinsson S, et al. (2022): The presence of serum anti-SARS-CoV-2 IgA appears to protect primary health care workers from COVID-19. Eur J Immunol 52: 800-809.
37.
Jain R, Mallya MV, Amoncar S, et al. (2022): Seroprevalence of SARS-CoV-2 among potential convalescent plasma donors and analysis of their deferral pattern: Experience from tertiary care hospital in western India. Transfus Clin Biol 29: 60-64.
38.
Steenhuis M, Mierlo G, Derksen NIL, et al. (2021): Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors. Clin Transl Immunology 10: e1285.
39.
Rangel-Ramírez VV, Macías-Piña KA, Servin-Garrido RR, et al. (2022): A systematic review and meta-analysis of the IgA seroprevalence in COVID-19 patients: Is there a role for IgA in COVID-19 diagnosis or severity? Microbiol Res 263: 127105.
40.
Kaneko Y, Sugiyama A, Tanaka T, et al. (2022): The serological diversity of serum IgG/IgA/IgM against SARS-CoV-2 nucleoprotein, spike, and receptor-binding domain and neutralizing antibodies in patients with COVID-19 in Japan. Health Sci Rep 5: e572.
41.
Zervou FN, Louie P, Stachel A, et al. (2021): SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection. J Med Virol 93: 5409-5415.
42.
Montaño Mendoza VM, Mendez Cortina YA, Rodríguez-Perea AL, et al. (2023): Biological sex and age-related differences shape the antiviral response to SARS-CoV-2 infection. Heliyon 9: e13045.
43.
Tsverava L, Chitadze N, Chanturia G, et al. (2022): Antibody profiling reveals gender differences in response to SARS-COVID-2 infection. AIMS Allergy Immunol 6: 6-13.
44.
Wagner A, Garner-Spitzer E, Jasinska J, et al. (2018): Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules. Sci Rep 8: 9825.
45.
Brockman MA, Mwimanzi F, Lapointe HR, et al. (2022): Reduced magnitude and durability of humoral immune responses to COVID-19 mRNA vaccines among older adults. J Infect Dis 225: 1129-1140.
46.
Williams KV, Moehling Geffel K, Alcorn JF, et al. (2023): Factors associated with humoral immune response in older adults who received egg-free influenza vaccine. Vaccine 41: 862-869.
47.
Buckley CE III, Dorsey FC (1970): The effect of aging on human serum immunoglobulin concentrations. J Immunol 105: 964-972.
48.
Challacombe SJ, Percival RS, Marsh PD (1995): Age-related changes in immunoglobulin isotypes in whole and parotid saliva and serum in healthy individuals. Oral Microbiol Immunol 10: 202-207.
49.
Crisp HC, Quinn JM (2009): Quantitative immunoglobulins in adulthood. Allergy Asthma Proc 30: 649-654.
50.
Lorent D, Nowak R, Roxo C, et al. (2021): Prevalence of anti-SARS-CoV-2 antibodies in Poznań, Poland, after the first wave of the COVID-19 pandemic. Vaccines (Basel) 9: 541.
51.
Zejda JE, Brożek GM, Kowalska M, et al. (2021): Seroprevalence of anti-SARS-CoV-2 antibodies in a random sample of inhabitants of the Katowice Region, Poland. Int J Environ Res Public Health 18: 3188.
52.
World Health Organization. One year since the emergence of COVID-19 virus variant Omicron [Internet] (2022). Available from: https://www.who.int/news-room/feature-stories/detail/one-year-since-the-emergence-of-omicron (cited 2023 Dec 10).
53.
Rzymski P, Pokorska-Śpiewak M, Jackowska T, et al. (2023): Key considerations during the transition from the acute phase of the COVID-19 pandemic: A narrative review. Vaccines 11: 1502.
